Illinois Federal Court Considers Whether Plaintiff Expert’s Methodologies Were Sufficiently Reliable under Daubert in a Pharmaceutical Case

GlaxoSmithKline has attempted to knock out the plaintiff’s experts in Dolin v. GlaxoSmithKline, in its latest round of Daubert motions. Wendy Dolin is suing GSK after the suicide death of her prominent lawyer husband, who had been taking the generic form of Paxil, paroxetine, an antidepressant.  This case made national news just a year ago when Judge Zagel of the Northern District of Illinois held that GSK could be liable for Dolin’s death under a negligence theory, not a product liability theory, even though…
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

Last Week’s Important Life Science Headlines

        Litigation
Continue reading...

This Week’s Science Headlines

        Litigation
Continue reading...

Pennsylvania Superior Court Upholds Dismissal of Suit Claiming Paxil Caused Birth Defects

The Pennsylvania Superior Court recently upheld the trial court’s ruling in Thomas v. SmithKline Beecham Corp., 27 Pa.D.&C. 5th 279 (Pa.Commw. Ct. 2012).  Thomas dismissed plaintiff’s wrongful death and survival claims based on her use of the antidepressant drug Paxil during pregnancy as time barred.  She ingested Paxil during her pregnancy and she was subsequently informed in 2001 that a fetal echocardiogram revealed that her fetus had congenital heart defects.  Three days later she chose to undergo a therapeutic abortion at less than…
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

This Week’s Life Science Headlines

        Litigation
Continue reading...

GlaxoSmithKline Announces $229 Million Settlement of Avandia Lawsuits

British drugmaker GlaxoSmithKline (GSK) announced on July 25th that it would pay $229 million to resolve lawsuits brought by eight U.S. states related to improper marketing of its diabetes drug Avandia (rosiglitazone).  In a regulatory filing, GSK said the settlement was within provisions it had previously set aside for litigation, and also resolved claims brought by the Attorney General of Louisiana involving other GSK products. The announcement by GSK explained that the settlements had been undertaken in order to avoid lengthy trials, and did…
Continue reading...